# **Special Issue**

# **Updates on Kawasaki Disease**

# Message from the Guest Editor

Kawasaki disease, first described by Dr. Tomisaku Kawasaki in 1967, is a febrile systemic vasculitis that primarily affects infants and young children. The development of coronary artery aneurysms, the most serious complication, can lead to acute coronary events such as myocardial infarction. Thanks to the development of acute treatments, the incidence of coronary sequelae in Japan remains at 2–3%, but the development of treatments aimed at eliminating all instances of coronary artery aneurysms is desirable. In recent years, according to a report by Burns et al., datadriven analysis has revealed that Kawasaki disease can be divided into four clusters, each with individual characteristics such as age at onset, response to treatment, and risk of coronary artery aneurysm. Based on these findings, we recognize that individualizing treatment methods for each cluster will be important in preventing future coronary artery aneurysm complications. We hope that this Special Issue will lead to future advances in the acute management and individualized treatment of Kawasaki disease.

#### **Guest Editor**

Dr. Eisuke Suganuma Saitama Children's Medical Center, Saitama, Japan

### Deadline for manuscript submissions

30 June 2026



an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/217597

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





# **About the Journal**

# Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

#### Editor-in-Chief

#### Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

#### **Author Benefits**

### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

## Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).